In which sequence does targeted and immuno therapy performs best in patients with metastatic melanoma? This question comes up almost daily in clinical practice. The phase II SECOMBIT trial might plant the seed that will give the answer in the nearby future. Professor Paolo Ascierto will bring you the results of this exciting study.
Click here to find the rest of our ESMO 2020 coverage.